EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 482 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO launches new principles for humanising scientific reporting to strengthen the... October 21, 2026 Thanks For Making This GivingTuesday Our Best One Yet! December 1, 2021 Carriers of a Germline Pathogenic Variant in CDKN2A are at a... June 17, 2022 Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... July 28, 2025 Load more HOT NEWS First-of-its-kind app for patients on clinical trials being piloted by Cancer... Screening for Many Cancers with One Test: Uncertainty Abounds Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment...
